Westin, J, Chavez, J, Schuster, SJ, Vucinic, V, Young, PA, Johnson, PC, Bramanti, S, Rambaldi, A, Meijide, JB, Kato, K, Sancho, JM, Kwon, M, Solano, C, Fleming, S, Dahiya, S, Garcia-Sancho, AM, Ramos, PM, Pearson, D, Diallo, S, Zia, A, Segura, E, Masood, A, Barba, P. Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results. BLOOD. 2025; 146DOI:10.1182/blood-2025-670. PMID:. IF:23.100(Q1/1D).

Barba, P, Rambaldi, A, Boissel, N, Doki, N, Blaise, D, Ciceri, F, Meijide, JB, Kwon, M, Fleming, S, Goñi, CB, Teshima, T, Kato, K, Balsat, M, Jaeger, U, Shune, L, Ramos, PM, Pearson, D, Corcoran, J, Zia, A, Foster, M, Masood, A, Dickinson, M. Phase 1 evaluation of the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). BLOOD. 2025; 146DOI:10.1182/blood-2025-811. PMID:. IF:23.100(Q1/1D).

Munárriz, D, Pérez-Lopez, E, Rodríguez, CM, Luque, M, Esquirol, A, Calvo, CM, Aparicio, C, Peña-Muñoz, F, Fernando, IH, Ormtegi, IO, Marín, AJS, Fernández-Luis, S, Domínguez-García, JJ, Fernández, SV, Lopez-Lorenzo, JL, Fleitas, CA, González-Rodriguez, AP, García, L, Torrado, T, Filaferro, S, Balsalobre, P, Cascon, MJP, Rovira, M, Salas, MQ. Donor age as an independent predictor of inferior outcomes after haploidentical hematopoietic cell transplantation in acute myeloid leukemia. Study conducted on behalf of GETH-TC. Frontiers in Immunology. 2025; 16DOI:10.3389/fimmu.2025.1700463. PMID:41394844. IF:5.900(Q1/2D).

Torres-Esquius, S, Gabarros-Subira, M, Gurnari, C, Bravo-Perez, C, López, GR, Arias, RD, Sanz, A, Martinez, MM, Beas, F, Jáuregui, SN, Arias, R, Canela, MP, Saumell, S, Voso, MT, Maciejewski, J, Acha, P, Valcarcel, D, Jerez, A, Montoro, MJ. Bone marrow alterations and clonal hematopoiesis in germline ETV6 mutation carriers without hematologic malignancy. BLOOD. 2025; 146DOI:10.1182/blood-2025-4997. PMID:. IF:23.100(Q1/1D).

Ubieto, AJ, Alós, DG, Dominguez, SR, Magnano, L, Sánchez, S, Vicente, FD, Iacoboni, G, Losada, CM, Manso, RG, Browne, S, Izquierdo, AR, Baumann, T, Bacelar, AG, Santaella, MP, Prieto, PG, De Villambrosia, SG, Bastos-Oreiro, M, Hernandez, AC, De Miguel, LB, Sturla, AL, Abellan, PF, Vidaller, PJP, Amutio, E, Toimil, FS, Pardal, E, Micó, M, Prat, AM, De La Cruz, B, Huerga, S, Landwehr, M, Hernández, I, Andreu, R, De la Cruz, J, Barca, EG. First-line therapy with rituximab vs. rituximab-CHOP in post-transplant monomorphic diffuse large B-cell lymphoma (DLBCL): Long-term real-world evidence from the spanish group of lymphoma (GELTAMO). BLOOD. 2025; 146DOI:10.1182/blood-2025-3677. PMID:. IF:23.100(Q1/1D).

Gurnari, C, Ottone, T, Piciocchi, A, Späth, D, Meid, A, Marsili, G, Fabiani, E, Romano, F, Pascale, MR, Chiusolo, P, Di Ianni, M, Sobas, M, Brunetti, L, Oñate, G, Infante, JB, Nanni, J, Vetro, C, Boada, M, Candoni, A, Sierra, J, Potter, N, Gilkes, A, Johnson, S, Thomas, I, Huntley, B, Russell, N, Dillon, R, Döhner, H, Döhner, K, Voso, MT. Diagnostic evaluation methods and prognostic impact of FLT3-ITD microclones in Acute Myeloid Leukemia (AML): A retrospective multicenter study on behalf of the EHA AML-specialized working group (SWG). BLOOD. 2025; 146DOI:10.1182/blood-2025-217. PMID:. IF:23.100(Q1/1D).

Hernández-Rivas, JA, Prat, AM, Ponce, ES, Medina, A, Lluch-García, R, Oliveira, ACD, Rodriguez-Fernandez, A, Soler, JA, Terol-Castera, MJ, Machado-Machado, P, Pérez-Encinas, M, Romero-Carmona, R, Segundo, LYS, García-Martin, P, Mompo, C, Zubillaga-Marban, E. First worldwide real-life data on fixed-duration ibrutinib plus venetoclax treatment for previously untreated CLL/SLL patients: Updated interim analysis of Spain's LI plus VE observational study. BLOOD. 2025; 146DOI:10.1182/blood-2025-2728. PMID:. IF:23.100(Q1/1D).

Niebla, AM, Gine, E, Bastos-Oreiro, M, Perez, A, Cabirta, A, Vicente, FD, Vilaseca, MC, Ubieto, AJ, De Villambrosia, SG, Prat, AM, Barca, EG, Henriquez, HDL, Herranz, ER, Prieto, PG, Cordoba, R, Carreres, AS, Garcia-Sancho, AM, Moya, AMGN, Grande, C, Martine, PP, Nicolas, C, Gutierrez, A, Rivas, JAH, Sanchez-Gonzalez, B, Villalobos, MT, Garcia-Cerecedo, T, Trillo, RA, Donato, E, Gutierrez, PV, Belmonte, DG, Cozzarelli, SRV, Ordoñez, SS, De La Mano, EP, Avaría, A, Blanco, LV, Roldan-Perez, A, Sancho, JM, De la Cruz, B, Prince-Eladnani, R, Abrisqueta, P. Characterization and outcomes of patients with indolent Mantle Cell Lymphoma (iMCL) in Spain. the GELTAMO-MCL-2022 Study. BLOOD. 2025; 146DOI:10.1182/blood-2025-3592. PMID:. IF:23.100(Q1/1D).